Skip to content
Homepage
Clinic directory

Clinics in Boston, Connecticut

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Boston, CT

Stem Cell Therapy clinics in Boston

Boston supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Massachusetts General Hospital, Brigham and Women's, Beth Israel Deaconess, and Boston Children's, and stem cell practice in the area spans the Longwood Medical Area, Back Bay, and Cambridge border. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Massachusetts regulates physician practice through the Board of Registration in Medicine. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. Harvard-affiliated hospitals and MIT anchor the region's academic trial infrastructure. The 4 Boston clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Massachusetts Board of Registration in Medicine licensure checks.

No clinics found

Try adjusting your filters or search terms

Reset all filters

Regulatory context

A note on Connecticut's stem cell therapy rules.

In Connecticut, cellular therapies are governed by federal rules at 21 CFR Part 1271. Minimally manipulated HCT/Ps for homologous use fall under Section 361 and do not require premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with another article are Section 351 biologics that require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, exosome, and culture-expanded mesenchymal cell therapies offered for orthopedic, neurologic, and longevity indications fall under Section 351 and lack FDA approval.

  • Connecticut General Statutes Chapter 370 (Medicine and Surgery)
    Establishes physician licensure under the Connecticut Medical Examining Board and disciplinary standards applicable to cellular therapy providers.
  • Connecticut General Statutes Chapter 400J (Naturopathy)
    Defines a limited naturopathic scope that does not authorize independent administration of cellular biologics.
  • Connecticut General Statutes Chapter 400u (Pharmacy)
    Regulates compounding pharmacies and aligns with federal 503A and 503B requirements.

The FDA has inspected and corresponded with Connecticut providers offering cellular and exosome therapies, and warning letters have been issued for unapproved biologic claims. The Connecticut Department of Public Health and the Medical Examining Board have authority to discipline physicians for unprofessional conduct, including misleading regenerative medicine advertising. The Connecticut Attorney General has used the Connecticut Unfair Trade Practices Act to investigate deceptive health claims. No widely publicized state injunction specific to stem cell clinics has been issued, but enforcement risk tracks federal action.

Sources: fda.gov · cga.ct.gov · portal.ct.gov

Stem Cell Therapy in Boston, answered.

Most stem cell therapies at private Boston clinics are not FDA-approved. The FDA has approved certain hematopoietic stem cell products for blood and immune disorders, but stem cell injections for orthopedic, neurological, or longevity use are generally investigational. They require a Biologics License or an active Investigational New Drug authorization, or they must qualify as Section 361 minimally manipulated and homologous-use products under 21 CFR Part 1271. Massachusetts regulates physician practice through the Board of Registration in Medicine.

Boston sits in the premium metro tier. Single-joint autologous bone marrow or adipose injections typically run $5,000 to $15,000 per session. Systemic IV protocols using allogeneic umbilical cord or Wharton's jelly products range $10,000 to $25,000, and full multi-session protocols can reach $20,000 to $50,000. Exosome add-ons range $4,000 to $8,000. Insurance rarely covers these treatments because the FDA classifies most protocols as investigational.

Autologous stem cells come from your own body, usually harvested from bone marrow aspirate or adipose tissue and reinjected the same day. When minimally manipulated and used for homologous function, they often fall under FDA Section 361, which does not require pre-market approval. Allogeneic stem cells come from a donor source, most commonly umbilical cord blood or Wharton's jelly, and are generally classified as Section 351 biologics that require an active Investigational New Drug authorization. Boston clinic offerings span both categories, so ask which classification applies before treatment.

Yes. Research programs at Massachusetts General Hospital, Brigham and Women's, Beth Israel Deaconess, and Boston Children's periodically run FDA-authorized stem cell trials across orthopedics, neurology, cardiology, and oncology. Search clinicaltrials.gov and filter by Boston or the broader metro to see active recruiting studies. Trial participation is typically low-cost or free compared to commercial protocols and includes structured follow-up with imaging and lab monitoring.

Verify physician licensure through the Massachusetts Board of Registration in Medicine and confirm the clinic's NPI number through the NPPES registry. Check the FDA warning letter database for the clinic name and the HHS Office of Inspector General exclusion list. Ask whether the treatment is Section 361 or Section 351, whether the clinic operates under an Investigational New Drug authorization for allogeneic or expanded products, and whether adverse events are tracked. Ask specifically about compliance with federal 21 CFR 1271.

Treatment guide

Learn about Stem Cell Therapy

What it is, how it works, and what to expect.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology